The article discusses the growing mainstream interest in microdosing psychedelics like LSD and psilocybin, particularly for claims of enhanced creativity and mood. However, rigorous clinical trials have found little to support these claims, with many effects resembling placebo outcomes. Notably, psychologist James Fadiman highlights the role of intention and belief as significant factors. A review from 2024 suggested subtle effects but lacked strong evidence linking microdosing to improved mental states. Despite the hype, the scientific community remains skeptical about the actual benefits derived from these substances.
...recent placebo-controlled studies have cast doubt on the pharmacological efficacy of microdosing psychedelics, suggesting that observed benefits may largely stem from participants' expectations.
James Fadiman asserts that the "reported and perceived changes in enhanced capacities and health conditions far exceed the possibility of just being explained by placebo and expectation effects."
Collection
[
|
...
]